Here, we show that cDC1 accumulation in mouse tumors often depends on natural killer (NK) cells that produce the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, intratumoral CCL5, ...

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma Phase I trial demonstrates AFM13-NK cells are safe and highly effective in heavily pretreated ...

Inflammatory cytokines (tumour necrosis factor α and interferon γ) and Toll-like receptor 3 ligands stimulate intratumoural production of chemokines especially CXCL10 and CCL5, which drive tumour ...

The CAR-NK program, dubbed CB-020, was an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 cell therapy aimed at solid tumors. Caribou already revealed in March that it had ...

Previous research has established that NK cell-derived CCL5 and XCL1 play a crucial role in recruiting cDC1 cells to the tumor microenvironment, contributing to tumor control. In this study, by using ...

Relatedly, previous studies, cited by the authors, reported that NK cells promote T cell activation by producing the chemokines CCL5 and XCL1, and FLT3 ligand, which respectively recruit and activate ...

Further investigation revealed that only CCL5 and GZMA were highly expressed in T and NK cells, where CCL5 mediated T and NK cell interaction with endothelial cells, smooth muscle cells, and ...

NK cells are further known to produce IFNγ and similar biomolecules capable of preventing metastasis by forcing malignant cells into a state of dormancy, and FLT-3L, XCL1, and CCL5, which bolster ...

48 To measure NK cell migration, we used Corning® Transwell® plates with inserts (pore size 5.0 μm, Cat# CLS3421). 650 μl R10 medium containing recombinant chemokines manufactured by Peprotech ...

This study, published today in Nature Medicine, demonstrated that a normal physiological process called trogocytosis contributes to tumor escape and poor responses after CAR NK cell therapy by ...

In hematologic oncology, advancements in chimeric antigen receptors (CARs) for T-cell therapy have led to new investigations and an emerging role for CAR-natural killer (NK) cell therapy. Here we ...